Replimune Group, Inc.: Form 10-Q for the period ended Dec 31, 2021
Filed with the SEC on Feb 3, 2022 and accepted by EDGAR at Feb 3, 2022, 08:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-10-01 to 2021-12-31 | $19.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-04-01 to 2021-12-31 | $57.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-10-01 to 2021-12-31 | −$29.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-04-01 to 2021-12-31 | −$86.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-10-01 to 2021-12-31 | −$29.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-04-01 to 2021-12-31 | −$86.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-10-01 to 2021-12-31 | −$0.57 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-04-01 to 2021-12-31 | −$1.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-10-01 to 2021-12-31 | −$0.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-04-01 to 2021-12-31 | −$1.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-10-01 to 2021-12-31 | 52,319,877 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-04-01 to 2021-12-31 | 52,104,548 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-04-01 to 2021-12-31 | −$59.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-04-01 to 2021-12-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-12-31 | $132.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $427.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $485.3m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $18.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $47.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $437.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001737953-22-000005. Last ingested by Listed: Nov 7, 2026, 12:41 ET. Listed shows no prices and gives no investment advice.